Rapid acute treatment of agitation in patients with bipolar I disorder: A multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine

Bipolar Disorders

Volumn 14, Issue 1, 2012, Pages 31-40

  Kwentus, Joseph ^a   Riesenberg, Robert A ^b   Marandi, Morteza ^c   Manning, Raymond A ^d   Allen, Michael H ^e   Fishman, Robert S ^f   Spyker, Daniel A ^f   Kehne, John H ^g   Cassella, James V ^f  

^a Precise Research Centers   (United States)

^b Atlanta Center for Medical Research   (United States)

^c Univ S Carolina Sch Med Vice P   (United States)

^d CNRI Los Angeles   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f Alexza Pharmaceuticals   (United States)

^g Translational Neuropharmacology Consulting   (United States)

Author keywords

Agitation; Bipolar I disorder; Clinical trial; Inhaled loxapine; Loxapine; Placebo controlled; Randomized; Rapid acute treatment; Staccato

Indexed keywords

LORAZEPAM; LOXAPINE;

ADULT; AGITATION; ANXIETY; ARTICLE; BIPOLAR I DISORDER; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; FEMALE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MIXED MANIA AND DEPRESSION; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE;

ADMINISTRATION, INHALATION; ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LOXAPINE; MALE; MIDDLE AGED; PSYCHOMOTOR AGITATION; TREATMENT OUTCOME;

EID: 84856884690     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2011.00975.x     Document Type: Article

References (32)

1. Osser DN, Sigadel R. Short-term inpatient pharmacotherapy of schizophrenia. Harv Rev Psychiatry 2001; 9: 89-104.
2. Conn DK, Lieff S. Diagnosing and managing delirium in the elderly. Can Fam Physician 2001; 47: 101-108.
3. Alderfer BS, Allen MH. Treatment of agitation in bipolar disorder across the life cycle. J Clin Psychiatry 2003; 64(Suppl. 4): 3-9.
4. Currier GW, Trenton A. Pharmacological treatment of psychotic agitation. CNS Drugs 2002; 16: 219-228.
5. Yildiz A, Sachs GS, Turgay A. Pharmacological management of agitation in emergency settings. Emerg Med J 2003; 20: 339-346.
6. Currier GW, Allen MH, Bunney EB et al. Standard therapies for acute agitation. J Emerg Med 2004; 27: S9-S12.
7. Battaglia J. Pharmacological management of acute agitation. Drugs 2005; 65: 1207-1222.
8. Citrome L. Interventions for the treatment of acute agitation. CNS Spectr 2007; 12: 8-12.
9. Nordstrom K, Allen MH. Managing the acutely agitated and psychotic patient. CNS Spectr 2007; 12: 5-11.
10. Zimbroff DL. Pharmacological control of acute agitation: focus on intramuscular preparations. CNS Drugs 2008; 22: 199-212.
11. Allen MH, Currier GW, Hughes DH, Reyes-Harde M, Docherty JP. The Expert Consensus Guideline Series. Treatment of behavioral emergencies. Postgrad Med 2001; May (Spec No): 1-88.
12. Breier A, Meehan K, Birkett M et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002; 59: 441-448.
13. Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2007; 68: 111-119.
14. Wright P, Birkett M, David SR et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001; 158: 1149-1151.
15. Battaglia J, Lindborg SR, Alaka K, Meehan K, Wright P. Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emerg Med 2003; 21: 192-198.
16. Heel RC, Brogden RN, Speight TM, Avery GS. Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent. Drugs 1978; 15: 198-217.
17. Chakrabarti A, Bagnall AM, Chue P et al. Loxapine for schizophrenia. Cochrane Database Syst Rev 2007: Art. No.: CD001943; doi:
18. Paprocki J, Versiani M. A double-blind comparison between loxapine and haloperidol by parenteral route in acute schizophrenia. Curr Ther Res Clin Exp 1977; 21: 80-100.
19. Fruensgaard K, Korsgaard S, Jorgensen H, Jensen K. Loxapine versus haloperidol parenterally in acute psychosis with agitation. A double-blind study. Acta Psychiatr Scand 1977; 56: 256-264.
20. Dubin WR, Weiss KJ. Rapid tranquilization: a comparison of thiothixene with loxapine. J Clin Psychiatry 1986; 47: 294-297.
21. Gaussares C, Gerard H, Bosc M. Interest in injectable Loxapine for severe agitation. L' Information Psychiatrique 1989; 69: 656-660.
22. Bourdinard V, Pochard F. Survey of management methods for patients in a state of agitation at admissions and emergency departments in France. L' Encephale 2003; 29: 89-98.
23. Glazer WM. Does loxapine have "atypical" properties? Clinical evidence J Clin Psychiatry 1999; 60: 42-46.
24. Spyker DA, Munzar P, Cassella JV. Pharmacokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteers. J Clin Pharmacol 2011; 50: 169-179.
25. Allen MH, Feifel D, Lesem MD et al. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011; 72: 1313-1321.
26. Lesem MD, Tran-Johnson TK, Riesenberg RA et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry 2011; 198: 51-58.
27. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276.
28. Kay SR, Sevy S. Pyramidical model of schizophrenia. Schizophr Bull 1990; 16: 537-545.
29. Rabinowitz JD, Wensley M, Lloyd P et al. Fast onset medications through thermally generated aerosols. J Pharmacol Exp Ther 2004; 309: 769-775.
30. Guy W. ECEU Assessment Manual for Psychopharmacology - Revised. Rockville: DHEW Publ N ADM 76-338, U.S. Department of Health, Education, and Welfare, 1976: 218-222.
31. Buckley PF. The role of typical and atypical antipsychotic medications in the management of agitation and aggression. J Clin Psychiatry 1999; 60: 52-60.
32. Allen MH, Currier GW. Use of restraints and pharmacotherapy in academic psychiatric emergency services. Gen Hosp Psychiatry 2004; 26: 42-49.